Treatment outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma: a single-center retrospective cohort study.
Tian Yi Y, Wei Li L, Li Li L, Ma Lin L
To describe outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma (KHE). We retrospectively reviewed children with KHE receiving oral β-blockers or sirolimus at Beijing Children's Hospital from January 2016 to April 2026. Lesion regression at fixed time points, treatment duration, treatment discontinuation, recurrence, and safety were assessed. Thirteen patients received β-blockers and 11 sirolimus, including three with prior therapy. Baseline lesion measurements did not differ significantly, but the β-blocker group was younger [median 4.0 (IQR, 3.0-4.0) vs. 19.0 (10.5-29.5) months; p < 0.001] and had lower frequencies of pain (23.1% vs. 72.7%; p = 0.038) and hyperhidrosis (0% vs. 54.5%; p = 0.003). Cumulative lesion-regression thresholds did not differ significantly through 9 months. At 9 months, >25%, >50%, and >75% regression occurred in 76.9%, 46.2%, and 23.1% with β-blockers versus 100.0%, 72.7%, and 18.2% with sirolimus, respectively. Treatment was discontinued in 9/13 and 3/11 patients (median durations, 40.0 and 18.0 months, respectively). No recurrence was observed after cessation. Safety events were reversible and manageable. In this cohort, both treatments were associated with improvement, but baseline imbalances limit direct comparison. β-blocker responses in predominantly younger, less symptomatic patients require confirmation in larger prospective studies.